This review of the current epidemiological literature on erectile dysfunction (ED) suggests that approximately 5–20% of men have moderate-to-severe ED. Different definitions of ED, age distributions and concomitant medical conditions, as well as methodological differences, may explain much of the variance in reported prevalence rates. Various chronic disorders are associated with elevated rates of ED including depression, diabetes, and cardiovascular and neurological diseases. Such disorders are more common in the elderly, which may partially explain the elevated prevalence of ED in men over 60 y of age. Currently, up to 70% of men with ED are not treated. However, so many men experience considerable distress from their condition, that the increasing awareness of ED as well as the availability of noninvasive treatments may result in a greater proportion of patients seeking treatment, and eventually regaining satisfaction with their sex life.
In this review, we aim to provide information on the prevalence of erectile dysfunction (ED) in the general populations of different countries, allowing generalisation of findings at the given population level. It complements the recently published systematic reviews by Lewis et al1 and by Simons and Carey,2 which both showed the heterogeneity of the published evidence. In addition, the prevalence of ED in groups with major comorbidities and its impact on the health-care system is discussed.
ED has been broadly defined as the inability to achieve or maintain an erection sufficiently rigid for satisfying sexual intercourse.3 ED can have a profound negative impact on the quality of life and life satisfaction of the patient (and his partner), resulting in fear, loss of self-image and selfconfidence, and depression.4,5,6,7
While some attention has been given to the potential impact of the introduction of oral treatments for ED,8,9 the nondrug costs of ED to the health-care systems remain unknown. Reimbursement for ED treatments have been rejected on the basis of assumed large prevalence rates, ignoring the fact that ED treatment rates may be much lower. Moreover, several studies have shown the economic efficiency of treating ED,10,11 that is, treatment for ED can buy much improvement in quality of life for a given budget.
When assessing the overall impact of a condition, epidemiological data are the cornerstone. Early insights were gathered by Kinsey in 1948.12 Epidemiological studies on ED using modern techniques appeared in the 1980s and several more have been published since.1,2,13 Comparisons of studies are, however, difficult because the terminology used to describe ED is inconsistent. This has led to conceptual confusion and difficulties in comparing published results. Consequently, in 1993, the NIH Concensus Development Panel recommended a more precise term of ED.3 This definition, however, encompasses three different categories: the inability to achieve an erection, the inability to maintain penile erection, and somewhat inconsistently, the notion of satisfaction with sexual performance. A number of different classifications have subsequently been used, such as those by Feldman et al,14 Rosen et al,15 Fugl-Meyer and Fugl-Meyer16 and Béjin.17
Special problems associated with epidemiological studies of ED include different age strata and (self-) selection bias. In addition, a variety of methodological approaches have been employed to elicit the answers, which again may bias a study.18
Studies of the prevalence of ED can be categorised into: nationally representative studies, regionally representative studies or selected, often clinical, series. The first two methods draw their representative samples from the population, and are generally forced to rely on self-reports of a condition. Selected clinical studies may focus on patients who consult a particular clinic, patients with a particular illness, patients who have been exposed to specific treatments, or other groups who may be expected to have a likelihood of having ED. They however give little or no information on the prevalence in the general population.
Population prevalence—current estimates and comparisons
Most epidemiological studies of ED have measured the prevalence of the condition. There is, to our knowledge, only one report on the incidence of ED that has an epidemiological approach.19 Hence, it is not possible to estimate whether the number of men with ED is increasing or decreasing.
In 741 Danish men aged 18–88 y, Ventegodt20 assessed that 5.4% of men reported decreased ability to achieve an erection (Table 1). The prevalence was relatively constant at about 2% for all age groups up to the mid-40-y olds, but was nearly 18% in those aged 58–88 y (Table 2). While ED seems to have a significantly negative effect on the quality of life in the younger age groups, this effect diminishes to almost zero in the group aged 58 y or above. The study did not ask for difficulties maintaining an erection and thus may have underestimated the total prevalence.
The impact of questionnaires vs interviews was highlighted in a small, but regionally representative group of 51-y-old Danish men.18 In the questionnaire, 5% reported more than occasional ED (Table 1), and an additional 15% indicated rare ED. However, a subset of 100 men who had not reported ED in the questionnaire were subsequently interviewed by their own physician: now 7% of them had moderate-to-severe ED and a further 19% had occasional impairment of erections.
In a Finnish large-scale national combined face-to-face and questionnaire study,21 996 male respondents (aged 18–74 y) reported an overall 6% prevalence of erection difficulties at least fairly often, while 49% had experienced erection difficulties of any degree during the previous year. Men's erectile ability appeared at its best around the age of 30 y, with only 1% of men reporting erectile difficulties fairly often. This increased to 32% for men aged 65–74 y. Similarly, at age 30, 65% of men experienced no erectile difficulty, this fraction was 40% at age 50, 20% at age 70. A total of 15% of men had had erectile difficulties for an extended period during their life. In men aged 70 y or older, this lifetime prevalence amounted to over 50%. The survey also asked females about males erectile disabilities. They tended to report partners' ED somewhat more frequently, with an overall prevalence of 9%.
A similar prevalence was reported in a Swedish national study to 18 to 74-y-old men (Table 1),7,16 using a method very similar to the Finnish one. While less than 0.5% of 1475 male respondents to the study had complete erectile failure at (attempted) intercourse during the past 12 months, approximately 5% reported erectile disabilities at least quite often, 9% quite rarely, 21% hardly ever and 66% never. Among the men with ED, about two-thirds felt that the disability caused them distress and among those 75% had a low level of sexual satisfaction. Among women from the same age strata, 4% perceived that their partner had ED, 74% of these felt that it caused them distress while 82% had a low level of sexual satisfaction.
In another study from Sweden, Malmsten et al22 included questions regarding impotence in a questionnaire mailed to over 10 000 randomly selected men aged 45 y or older. ED was reported by 8% of respondents and was found to increase linearly with age up to 80 y. While 2% of men 45 y reported the condition, this increased to 18% for men aged 80 y. The proportion of men who remained sexually active fell linearly from 76% at age 45 y to about 17% at age 80 y.
A German regionally representative study23 employed a questionnaire that had been correlated with tumescence measurements in a validation study.24 The overall prevalence of ED in at least half of sexual attempts among the 4900 responders aged 30–80 y was 19% (Table 1). Men were asked whether they were dissatisfied with current sex life, and only 7% of the total cohort reported both ED and a dissatisfaction with sex life. This correlation showed a downward trend, with 61% of ED men aged 30–39 y being dissatisfied, but only 14% of those aged 70–79 y.
In a regional Dutch study of 1233 men aged 40–79 y,25 13% reported having difficulties getting an erection. Prevalence increased with age from 6, 9, 22 and 38% in men aged 40–49 y, 50–59, 60–69 and 70–79 y, respectively. However, using the Sexual Function Inventory26 to assess the prevalence, rates successively increased from 3 to 12, 33 and 64% in the respective age groups. While all men with ED in the group aged 40–49 y considered this a problem, only 16% of men aged 70–79 y considered their ED as bothersome. Men with ED also reported a significantly lower quality of life than comparators without ED.
In another regional Dutch study of 1960 men aged 50–78 y,27 the prevalence of severe ED was 3% in men 50 to 54 y old and 26% in men 70–78 y. Any degree of erectile disability was reported by 22 and 55% of the two respective age groups. Of men with mild ED, 8% considered this to be a problem for them, compared with 38% of men with moderate-to-severe ED. The percentage of men with moderate-to-severe ED who considered their condition a problem, remained relatively constant in men aged 50–69, but diminished to 21% of men in the oldest age group.
In France,28 11% of 1037 men aged 18–70 y responded by a self-administered questionnaire that they suffered from ED in at least 50% of sexual encounters, while an additional 28% indicated that they had erectile difficulties at least occasionally (Table 1). Prevalence was relatively constant up to 40 y, however, it increased markedly thereafter with a prevalence of 67% for any degree of ED in the oldest cohort.
Béjin17 in a nationally representative study that used telephone interviews in a large French sample aged 18–69 y, reported an overall ED prevalence of 47%. Of the men, 7% indicated having frequent erection difficulties, 12% sometimes, and an additional 28% experienced erection difficulties only occasionally. Again, this study demonstrates a strong correlation of ED and age, with 73% of men aged 18–19 y indicating that they never experienced any ED, whereas this prevalence is 62% in men aged 25–34 y, 44% in men aged 45–54 y, and 34% in men aged 55–69 y.
In recent Spanish population-based study,29 1857 men aged 25–70 y were interviewed and responded to a self-administered questionnaire. The prevalence of ED was assessed in two ways, with a single question on whether the respondent had any erectile disability, and with the International Index of Erectile Function (IIEF).15 With the single question, the overall prevalence of any degree of ED was 12%, with 5% reporting minimal ED, 5% moderate ED, and 2% severe/complete ED. Prevalence by IIEF definitions was 19, 16, 2 and 0.6%, respectively (Table 1). Prevalence of any ED rose from 8% in men aged 25–39 y to 48% in men 60 to 70-y old, while the prevalence of moderate/severe ED was 4 and 32%, respectively.
The Massachusetts Male Aging Study (MMAS)14 was a regional survey of 1709 men aged 40–69 y. Of the 1290 men who completed a paper questionnaire, 52% reported ED (Table 1), with 10% having complete, 25% moderate and 17% minimal ED. The probability of complete ED at age 70 was three-fold that at age 40, the probability of moderate ED was two-fold, while that of minimal ED remained constant across all age groups. While the MMAS is representative of the population in Massachusetts, it is limited in terms of sociocultural diversity (96% of the study population was white). In a long-term follow-up investigation of this study,19 the crude incidence rate for ED was 26/1000 man years; increasing with age from 12/1000 to 30/1000 and 46/1000 for men aged 40–49, 50–59 and 60–69 y, respectively.
In another US county-based study with 2115 respondents, those aged 40–79 y were asked about their ability to have erections when sexually stimulated. ED was defined as having erections little or none of the time when stimulated. While in the youngest cohort, only 1% had such severe ED, this increased to 25% for the oldest age group. Overall, the prevalence of ED was 11.6% (Table 1.)30
In a reasonably nationally representative US study focussing on a relatively younger population (18–59 y of age), one dichotomous question on trouble maintaining or achieving an erection was asked in a face-to-face interview. Since participants were requested to mention the presence of a critical symptom or problem during the past 12 months, it may be assumed that the question elicited the range of moderate-to-severe ED. An overall prevalence of ED of 10% (of 1244 respondents) was reported (Table 1).31 Prevalence was 7% in the 18 to 29-y age group and was 18% in those 50 to 59-y old. This study assessed the impact of ED on quality of life, and found a significant correlation of ED with low sexual satisfaction and low general happiness.
In a relatively small-scale study32 representative for South Australia, male participants over 40 y of age were invited to respond to a mailed questionnaire. Of the 392 respondents (53% of target), 22% indicated difficulty in obtaining an erection, 23% indicated erections less than half the time when wanted, and 26% erections inadequate for intercourse (Table 1). There was a significant correlation with age, 7% of the 40 to 49-y–old group, 36% of the 60 to 69-y-old group and 92% of the 80-y-old group and over reported erection difficulties.
In a Turkish interview, investigation of a randomly stratified sample (n=1982) of men aged >40 y, a preliminary report has shown that the overall age-adjusted prevalence of ED occurring usually or always was 36%. Also here, a pronounced effect of age was found. Thus, among 40 to 45-y olds, the prevalence of moderate and severe ED was 8% but at age 70+ it was as high as 90%.33
Besides these investigations, we have not been able to locate truly epidemiological data on the prevalence of ED. Thus, there is a deplorable lack of such data from the majority of the global population.
This review indicates that commonly age, and in particular relatively high age, has a major impact on the prevalence of ED although the overall prevalence of moderate-to-severe ED is profoundly different from a low of about 5% (Northern Europe) to a high of 35% (Massachusetts). These differences may be partly explained by different thresholds of definitions of moderate-to-severe ED. Another explanation is the different age distribution. Differences may be further explained by the technique chosen (phrasings of questions, choice of interviews or questionnaires, and perhaps whether or not the investigation is biased by being filled in at home or performed under controlled circumstances).
Factors affecting the prevalence of ED
A large number of factors have a negative impact on the erectile ability. A number of them were surveilled by Lewis et al.1 Most prominent ones are medical conditions such as vascular diseases, neurological deficits, mood, iatrogenic factors and endocrinological conditions. Besides, other parameters including perceived health, social status and other diagnosed conditions can result in ED. For some of these conditions, the causal aspects on ED are widely accepted: however, it is not well understood which impact they have on prevalence. Despite the scarcity of data and the fact that there are no real epidemiological studies on patients with important comorbidities, the sections below aim to shed some light on the prevalence of ED in such patients.
Cardiovascular diseases including coronary heart disease, myocardial infarction, hypertension, hyperlipidaemia and peripheral vascular disease have a close correlation with ED. In prospective study,34 it has been suggested that ischaemic heart disease and ED share important risk factors (smoking, obesity, hypertension and dietary factors). In agreement with these findings, Blanker et al27 found that smoking, obesity and treatment for cardiovascular problems were among significant risk factors. Complete impotence has been reported to be as common as 39% in those with treated heart disease;14 this was four-fold the prevalence in the overall study population. In Germany,23 prevalence of ED in hypertensives was 36% as compared to 19% in the overall population, and 16% in normotensives. ED prevalence was even higher in patients with heart failure (58%) (Braun, personal communication). Finally, the Finnish study also21 reported a two-fold increase in ED in hypertensive men.
In a report by Wei et al,38 there was a significant correlation between high concentrations of serum total cholesterol and ED. In the MMAS, total cholesterol was not correlated with ED but high-density lipoprotein cholesterol was inversely correlated with the prevalence of ED.14 The association between hyperlipidaemia and ED has been repeatedly described39 but some reports suggest that increased ED is associated with the use of hypolipidaemic drugs rather than hyperlipidaemia or atherosclerosis per se.40 Clearly, more work is needed to clarify the role of lipid levels in ED.
Diabetes mellitus appears to be a manifest risk factor for ED. In Massachusetts, the age-adjusted prevalence of complete impotence was 28% in treated diabetics against 10% in the total study population.14 In Spain,29 a four-fold greater likelihood of ED emerged for men with diabetes compared with nondiabetic men. Moreover, 60% of Germans with diabetes as compared to 19% in the study population had ED23 (Braun, personal communication).
Weinhardt and Carey,41 based on a literature review of controlled studies, found an about four-fold higher prevalence of ED in diabetic men than in controls.
In a large cross-sectional study42 of 10 000 Italian diabetic men, 36% reported ED. The prevalence increased from 5% in men aged 20–29 y to 46% in those aged 60–69 y. In men with ED, 30% reported complete and 70% incomplete erectile disability. Prevalence increased with the duration of diabetes as well as with insufficient metabolic control. ED appeared particularly prevalent in patients with retinopathy, neuropathy or nephropathy.
We have not been able to locate truly epidemiologically based reports on the impact of neurological disease and injuries on erectile ability. On the other hand, there is a body of reasonably convincing data based on clinical series, indicating that ED is a common companion to many neurological conditions. The literature on this subject has recently been surveyed by a task force on neurosexology.43
Brain damage is frequently followed by ED, and about 50–65% of men who have sustained a manifest stroke have been found to have moderate-to-severe ED.44 The prevalence of ED in long-term survivors of traumatic brain injury is in some studies less than 10%, others have found a prevalence of ED from 40 to 70%.44,45 It should be remembered, however, that traumatic brain injury is most common in people younger than 30 y. Parkinson's disease has also been described as being accompanied by ED in about 50% of cases.43 In a review of 24 studies, Lundberg et al46 reported that a median of 80% among more than 2500 men with spinal cord injuries could achieve erections without therapeutic assistance, with a much higher prevalence of ED in those with complete lower sacral injuries (about 75%) than in those with complete upper or incomplete cord lesions (<10%). Other conditions that are often associated with ED are hypothalamo–pituitary disorders (in particular, pituitary adenoma), epilepsia (especially frontal lobe engagement), multiple sclerosis and different disorders of the spinal cord and peripheral nerves.
Mood and depression
Several studies have shown that there is an association between depression and male ED. ED has been observed to increase with the severity of depression. At the maximum degree of depression, the age-adjusted probability of moderate-to-severe impotence was nearly 90%, as compared with 59% for medium-grade depression and 25% for mildly depressed men in the Massachusetts study.14
Using data from the same study, Araujo et al47 further investigated the association between ED and depression. The prevalence of depressive symptoms was constant across the age range in this cohort, averaging some 12%. After adjustment of potential confounders including age, depression was associated with a nearly two-fold increased likelihood for ED than in nondepressed controls. The use of antidepressant medications, which may also increase the prevalence of ED,48 did not affect the odds ratio.47
Besides the illnesses associated with ED, there are a number of medical interventions and treatments that impact on the sexual abilities. ED secondary to prostatectomy for cancer is probably one of the most common problems; however, no epidemiological studies assessing the prevalence of ED in these men could be found. In clinical series, rates of ED show high variability and depend on the method of intervention. Stanford et al49 investigated the outcomes of radical prostatectomy in 1291 men aged 39–79 y. Among men who had no ED before surgery, the proportion of men reporting impotence at follow-up was 66% for non-nerve-sparing surgery, 59% for unilateral surgery, and 56% for bilateral nerve-sparing surgery. Catalona et al50 assessed ED in 858 men in a consecutive series at one clinic: erections returned in 68% of men with bilateral nerve-sparing surgery as compared to 47% in men with unilateral nerve-sparing surgery. A study in men treated for prostate cancer51 assessed that 69% of men had erectile function sufficient for intercourse before treatment. Only 10% of men who underwent radical prostectomy and 15% of men with beam radiation therapy regained erectile function. According to recent studies, surgery for benign prostatic hyperplasia results in less ED than cancer surgery, leaving sexual function almost stable for most patients52,53 and modern minimally invasive procedures appear associated with even less adverse effects.54,55
It has been repeatedly reported that around 25% of erectile disabilities seen in medical practice are drug-induced.56,57 In the MMAS, diuretics and benzodiazepines were strongly associated with an increased prevalence of ED that persisted after correction for confounding factors.58 ED affected 10–20% of men taking thiazide diuretics, and to a lesser extent patients who are on betablockers. Antihypertensive drugs are particularly often reported to cause ED. This is the case for betablockers, Ca-channel blockers (CCBs), ACE inhibitors and angiotension-2 antagonists. Most likely, the lowered blood pressure is the cause; hence, the risk of causing ED by prescribing an antihypertensive is proportional to its effect. Fibrates and statins for lowering blood lipids have also been reported to cause ED. Very little data are available that help to estimate the prevalence of ED in those patient groups.
ED is a commonly reported side effect of histamine-receptor antagonists for treatment of gastric ulcers. Moreover, some of the NSAID drugs have been reported to cause ED. These drugs are prostaglandin inhibitors and may thus be antierectogenic. Drugs that depress or sedate the central nervous system (eg, tranquillisers, opiates, oestrogen and antidepressants) may be associated with ED.59
In a survey of the literature, Kim et al60 reached the suggestion that psychogenic (erotogeneous) erections as opposed to spontaneous (ie nocturnal) erections are only partly androgen-dependent. On the other hand, to an unknown extent, the fact that relative male hypogonadism increases with increasing age may be one background for the increased prevalence of ED and perhaps more clearly of decreased level of sexual desire in older men. This may partially explain the age-dependent lower level of problems and dissatisfaction because of erectile disabilities. Recently, however, Rhoden et al61 in men aged 40–90 y regardless of age found no significant differences in total serum testosterone level between those with different degrees of ED and those with or without ED.
A number of physical and psychological conditions are widely described to be associated with greatly increased prevalence of ED. So far, it remains difficult to estimate the prevalence rates in most such patient groups since very little epidemiological data are available.
Consultation rates for men with ED
When considering the impact of ED on the health-care system, the accurate assessment of the prevalence is only the starting point. A man who reports ED firstly registers a lack of erectile activity. Secondly, the distress this physical dysfunction causes him must be considered. This can be characterised as an aspiration-achievement gap.16 As pointed out in the DSM-IV,62 distress caused by ED is clinically more important than ED per se. While having ED and feeling that this causes distress is prerequisite for a man to consider seeking treatment for ED, there are other additional important determinants for actually requesting an appointment. These can include having a partner who is interested in sexual activity and who does not suffer herself from sexual disabilities. This is a very relevant parameter, since female sexual dysfunctions themselves have a prevalence rate in the range of 40–50%,7,31,20 and ED is to a significant extent accompanied by female partners having one or more sexual dysfunctions.63
Moreover, ED is often accompanied by other male sexual dysfunctions, including low desire and ejaculation problems. Other factors must be recognised as having an impact on the men's willingness to seek treatment for ED, including the fact that few people manage to openly discuss ED, because the majority consider it a taboo.64
Only a relatively small percentage of men with ED consider seeking counselling or treatment. In Finland,21 one-third of men with ED had consulted a physician. In Sweden,7 approximately one-third of men with ED sought advice6 but only few of them consulted a medical expert.7 Generally, it appears that about 30% of men with ED have sought treatment,5,65 but still fewer actually receive treatment.66,67
It has been assumed that the availability of convenient treatments has an impact on the diagnosis and treatment rates for ED. Skaer et al68 reviewed data from the US National Ambulatory Medical Care Survey for the years 1990–1998 and found a significant increase in the rate of physician–patient encounters for ‘a complaint (of ED) as a reason for requesting an appointment’ and/or ‘a diagnosis of ED’. In 1990, there were 17 encounters for a complaint of ED and 15 diagnoses of ED/1000 US male population. While the number of visits was relatively stable between 1990 and 1995, a significant increase occurred in 1996 to 25 encounters/1000 men for a complaint and 28/1000 for a diagnosis of ED. This rate stayed at this level until the end of 1998. The introduction in 1998 of PDE-5 inhibitor treatment did not immediately appear to influence the established upward trend in the number of encounters. A look at the prescribing of sildenafil in the same survey, however, showed that only in 41% of patients prescribed sildenafil was a diagnosis of ED recorded, and only in 33% was a complaint of ED given as a reason for the appointment. This highlights that there may be an under-reporting of ED in the physician files.
Large variations in the prevalence of ED have been observed in a number of studies. To some extent, differences probably reflect variations in definitions, methodology and study populations. The MMAS is often cited pertaining to ED prevalence. However, the Massachusetts 35% prevalence of moderate-to-severe ED is considerably higher than the 5–20% reported by most others. Information on prevalence rates in higher risk subgroups of the population is rather scarce. More epidemiological work is required to generate solid assumptions on prevalence rates in such subgroups of the population.
Only when the ED results in distress, can it be considered a clinically relevant condition. It has been shown in a number of studies that a subset of 30–70% of men with ED suffer distress from having ED. Thus, it appears that the prevalence of ED requiring clinical attention is in the range of 3–7%, and is therefore about 10-fold less than what has been communicated in several publications on ED. For several reasons, treatment rates of ED are clearly lower than the prevalence rates. These estimates should send a positive message to health-care payors that are currently excluding reimbursement of a medically relevant condition.
Lewis R, Hatzichristou D, Lauman E, McKinley J . Epidemiological and natural history of erectile dysfunction; risk factors including iatrogenic and aging. In: Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R (eds). Erectile Dysfunction. Plymbridge Distributors Ltd, Plymouth PL 6 7PY, United Kingdom, 2000, pp 19–51.
Simons JS, Carey MP . Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001; 30: 177–219.
NIH Consensus Development Panel on Impotence. Impotence. NIH Consensus Development Panel on Impotence. Am Med Assoc 1993; 270: 83–90.
Krane RJ, Goldstein I, Saenz de Tejada I . Impotence. N Engl J Med 1989; 321: 1648–1659.
Fugl-Meyer AR, Branholm IB, Fugl-Meyer KS . Happiness and domain-specific life satisfaction in adult northern Swedes. Clin Rehabili 1991; 5: 25–33.
Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS . On life satisfaction in male erectile dysfunction. Int J Impot Res 1997; 9: 141–148.
Fugl-Meyer KS . Chapter 12 Sex in Sweden: On the Swedish Sexual Life. The National Institute of Public Health. Stockholm, 1998, pp 218–234.
Fendrick AM . Access to innovative treatment of erectile dysfunction: clinical, economic, and quality-of-life considerations. Am J Manage Care 2000; 6 (Suppl 12): S632–S638.
Tan HL . Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. Pharmacoeconomics 2000; 17: 77–107.
Stolk EA et al. Cost utility analysis of sildenafil compared with papaverine–phentolamine injections. BMJ 2000; 320: 1165–1168.
Smith KJ, Roberts MS . The cost-effectiveness of sildenafil. Ann Intern Med 2000; 132: 933–937.
Kinsey AC . Sexual Behaviour in the Human Male. W B Saunders: Philadelphia, 1948.
Spector IP, Carey MP . Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 1990; 19: 389–408.
Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.
Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessments of erectile dysfunction. Urology 1997; 49: 822–830.
Fugl-Meyer AR, Fugl-Meyer K . Sexual disabilities, problems and satisfaction in 18–74 year old Swedes. Scand J Sexol 1999; 2: 79–105.
Béjin A . The epidemiology of premature ejaculation and of its association with erectile dysfunction. Adrologie 1999; 9: 211–225.
Solstad K, Hertoft P . Frequency of sexual problems and sexual dysfunction in middle-aged Danish men. Arch Sex Behav 1993; 22: 51–58.
Johannes CB et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460–463.
Ventegodt S . Sex and the quality of life in Denmark. Arch Sex Behav 1998; 27: 295–307.
Kontula O, Haavio-Mannila E . Sexual Pleasures. Enhancement of Sex Life in Finland, 1971–1992. Dartmouth Publishing Company: Aldershot, 1995.
Malmsten UG, Milson I, Molander U, Norlen LJ . Urinary incontinence and lower urinary tract symptoms: an epidemiological study of men aged 45 to 99 years. J Urol 1997; 158: 1733–1737.
Braun M et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.
Braun M et al. KEED-erster deutschspraching validierter Fragebogen zur Erfassung der männlichen sexuallen Funktion. Aktuel Urol 1998; 29: 300–305.
Meuleman EJ et al. Erectile dysfunction: prevalence and effect on the quality of life; Boxmeer study. Neder Tijdschr Geneesk 2001; 145: 576–581.
O'Leary MP et al. A brief sexual function inventory for urology. Urology 1995; 46: 697–706.
Blanker MH et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763–768.
Virag R, Beck-Ardilly L . Nosology, epidemiology, clinical quantification of erectile dysfunction. La Revue Med Interne 1997; 18 (Suppl 1): 10s–13s.
Martin-Morales A et al. Prevalence and independent risk factors for ereticle dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–575.
Panser LA et al. Sexual function of men aged 40 to 79 years: the Olmsted County Study of urinary symptoms and health status among men. J Am Geriatri Soc 1995; 43: 1107–1111.
Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.
Pinnock CB, Stapleton AM, Marshall VR . Erectile dysfunction in the community: a prevalence study. Med J Austr 1999; 171: 353–357.
Ergen A et al. Prevalence and correlates of erectile dysfunction in Turkey. A population-based study. Poster presented at the ESIR Congress, 2001.
Feldman HA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328–338.
Wabrek AJ, Burchell RC . Male sexual dysfunction associated with coronary heart disease. Arch Sex Behav 1980; 9: 69–75.
Sjögren K, Fugl-Meyer AR . Some factors influencing quality of sexual life after myocardial infarction. Int Rehabil Med 1983; 5: 197–201.
Diokno AC, Brown MB, Herzog AR . Sexual function in the elderly. Arch Intern Med 1990; 150: 197–200.
Wei M et al. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140: 930–937.
Virag R, Bouilly P, Frydman D . Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181–184.
Bruckert E, Giral P, Heshmati HM, Turpin G . Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21: 89–94.
Weinhardt LS, Carey MP . Prevalence of erectile disorder among men with diabetes mellitus: comprehensive review, methodological critique, and suggestions for future research. J Sex Res 1996; 33: 205–214.
Fedele D et al. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 1998; 21: 1973–1977.
Lundberg PO et al. Neurosexology. Eur J Neurol 2001; 8 (Suppl 3): 2–24.
Fugl-Meyer AR, Fugl-Meyer KS, Lundberg PO . Sexual rehabilitation. In: Frommelt P. Grötzbach (eds). Neurorehabilitation. Blackwell: Oxford, 1999, pp 370–388.
Elliott M, Biever LS . Head injury and sexual dysfunction. Brain Injury 1996; 10: 703–717.
Lundberg PO et al. Neurological disorders: erectile and ejaculatory dysfunction. In: Jardin A, Wagner G, Khoury S et al (eds). Erectile Dysfunction. 1999, pp 591–646.
Araujo AB et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998; 60: 458–465.
Mitchell JE, Popkin MK . Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983; 3: 76–79.
Stanford JL et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354–360.
Catalona WJ, Carvalhal GF, Mager DE, Smith DS . Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433–438.
Siegel T et al. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001; 165: 430–435.
Leliefeld HHJ, Stoevelaar HJ, McDonnell J . Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 2002; 89: 208–213.
Kunelius P, Häkkinen J, Lukkarinen O . Sexual functions in patients with benign prostatic hyperplasia before and after transurethral resection of the prostate. Urology Res 1998; 26: 7–9.
Francisca EAE et al. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol 1999; 161: 486–490.
Mutscher R et al. Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: a prospective multicenter clinical trial. J Urol 2000; 164: 1565–1569.
Slag MF et al. Impotence in medical clinic outpatients. JAMA 1983; 249: 1736–1740.
O'Keefe M, Hunt DK . Assessment and treatment of impotence. Med Clini North Am 1995; 79: 415–434.
Derby CA, Barbour MM, Hume AL, McKinlay JB . Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001; 21: 676–683.
Benet AE, Melman A . The epidemiology of erectile dysfunction. Urol Clini North Am 1995; 22: 699–709.
Kim YC et al. Endocrine and metabolic aspect in including treatment. In: Jardin A, Wagner G, Khoury S et al. (eds). Erectile Dysfunction, Plymbridge Distributor Ltd, Plymouth, United Kingdom, 1999; pp 205–240.
Rhoden EL et al. Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction? Int J Impot Res 2002; 14: 167–171.
Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association, 1994.
Fugl-Meyer KS, Fugl-Meyer AR . Sexual dysfunctions are not singularities. Int J Impot Res 2002. (Submitted).
Morales A, Choi H, Giami A et al. Socio-cultural, educational and ethical aspects of erectile dysfunction. In: Jardin A, Wagner G, Khoury S et al. (eds). Erectile Dysfunction, Plymbridge Distributor Ltd, Plymouth, United Kingdom, 1999; pp 575–590.
Ansong KS, Lewis C, Jenkins P, Bell J . Help-seeking decisions among men with impotence. Urology 1998; 52: 834–837.
Chew KK et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41–45.
Alonso Sandoica E et al. Impotence in diabetics: its prevalence and social-health implications. Atención Primaria 1997; 20: 435–439.
Skaer TL, Sclar DA, Robinson LM, Galin RS . Trends in the rate of self-report and diagnosis of ereticle dysfunction in the United States 1990–1998. Dis Manage Health Outcomes 2001; 9: 33–41.
This review was supported by a nonrestricted grant from Bayer AG.
About this article
Cite this article
Kubin, M., Wagner, G. & Fugl-Meyer, A. Epidemiology of erectile dysfunction. Int J Impot Res 15, 63–71 (2003). https://doi.org/10.1038/sj.ijir.3900949
- erectile dysfunction
- risk factors
Short-term intracavernous self-injection treatment of psychogenic erectile dysfunction secondary to sexual performance anxiety in unconsummated marriages
International Journal of Impotence Research (2021)
Socioeconomic status and barriers for contacting the general practitioner when bothered by erectile dysfunction: a population-based cross-sectional study
BMC Family Practice (2020)
Infrapubic approach for placement of inflatable penile prosthesis: contemporary review of technique and implications
International Journal of Impotence Research (2020)
Development of a novel topical formulation of glyceryl trinitrate for the treatment of erectile dysfunction
International Journal of Impotence Research (2020)
SN Comprehensive Clinical Medicine (2020)